Advances in the Application of Adjuvant Chemotherapy and Targeted Therapy in Postoperative Patients with Stage Ⅰ Lung Adenocarcinoma
Lung cancer is one of the main causes of cancer burden and death in China,with nearly 800,000 newly diagnosed lung cancer patients each year,nearly half of whom are lung adenocarcinoma(LUAD)patients.According to cur-rent clinical guidelines,surgery is the main treatment for stage Ⅰ LUAD patients,but the 5-year overall survival rate of stage ⅠLUAD patients alone is still unsatisfactory,about 73％-90％,indicating that a considerable number of patients require other means to improve survival benefits.Chemotherapy and targeted therapy have achieved great success in the treatment of locally advanced and metastatic LUAD patients,but there is still controversy over whether they can benefit stage Ⅰ LUAD postopera-tive patients.Under the circumstances,many researchers have paid attention to this issue and made beneficial explorations.This review provides a brief review of the factors that affect the acceptance of adjuvant chemotherapy and targeted therapy in stage ⅠLUAD postoperative patients,as well as the relevant clinical research on the application of adjuvant chemotherapy and targeted therapy in stage Ⅰ LUAD postoperative patients,in order to gain a broader understanding of the latest developments in this field and find new breakthroughs to promote sustained research in this field.
万方数据
维普
